SAN Sanofi

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

 

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

Paris, February 5, 2024. Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses*. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location.

Natalie Bickford

Chief People Officer, Sanofi

Many of us will face cancer one way or another in our lives. The last thing you want to be thinking about when you are diagnosed with cancer, or going through treatment, is work. And yet, half of people who receive a cancer diagnosis are frightened to tell their workplace. That is not right. I am delighted that Sanofi has gone further, guaranteeing job security and salary continuation for at least a year after diagnosis. Today, we also support every Sanofi employee facing cancer by training a global network of affinity groups who can provide safe spaces, and by helping managers understand the challenges their team members may be facing, and how best to approach them for reassurance and support.”

On top of financial support, employees will be able to incorporate further flexible work arrangements to better navigate cancer and work. The program also addresses the emotional wellbeing of Sanofi employees impacted by cancer and other critical illnesses. They will have access to a network of volunteer colleagues trained to help them navigate from initial diagnosis through the treatment journey and return to work.

Many of the volunteers in the network have experienced cancer; connecting with them creates a safe space for sharing experiences, discussing accessible resources and building supportive relationships. Impacted employees have also access to an external psychological support in all countries 24/7 through the Employee Assistance Program.

In addition, throughout 2024, Sanofi intends to implement coverage of miscellaneous non-medical expenses. Moreover, Sanofi permanent employees will become eligible for an unpaid caregiver leave which allows them to carry out caregiving duties for their close family member suffering from a critical illness*.



The program is also designed to better equip managers to support members of their team who are affected by cancer. It connects them with the knowledge they will need to take that first step in helping a colleague navigate their local benefit and support programs.

A global program inspired by an employee initiative

In 2017, several volunteer employees in France, with complementary expert skills and experience as patients, caregivers or managers, started the initiative. They first created space for affected employees to share their experience, ask questions, and hear from colleagues who have been through similar situations and found ways to reconcile work and illness. Importantly, they helped develop the right support the affected employee needs within their team. These groups can be called upon at any time, when learning the diagnosis, during treatment, during leaves, upon return to work, and in the years that follow.

The program has since grown to a network of 27 partner teams with one team at each Sanofi site in France, with 150 members who share feedback and best practice. More than 350 employees have benefited (42% sick employees, 30% caregivers, 28% managers).

The global program announced today echoes the original approach and makes Sanofi an ever more inclusive culture where everyday experiences matter for every employee worldwide. This wraps the program into a wider DE&I cultural transformation at Sanofi as the company drives Diversity, Equity, and Inclusion (DE&I) in and beyond the workplace.

Global impact of cancer and work

Of all chronic conditions, cancer had the highest prevalence of work loss. Research shows that the risk of losing a person's job in the EU increases 1.4 times after a cancer diagnosis1. According to an article published in the Journal of the National Cancer Institute, cancer-related employment changes are experienced by more than 40% of cancer survivors who were employed at or after diagnosis in the US2.

Worldwide, the number of people diagnosed with cancer who are of working age is significant. For example, around 45% of people diagnosed in the U.S. in 2020 were between 20–64 years old3. In France, around 160, 000 of the 400,000 people newly diagnosed with cancer were of working age and in the UK, around 900,000 people of working age are living with cancer.

In a recent Harris poll conducted last year in the U.S. by Cancer & Careers, 35% said that in general, those with cancer face stigma in the workplace. Yet, that same study revealed 78% felt that people who have been diagnosed with cancer and receive support from their employer are more likely to thrive in the workplace.

About Sanofi DE&I strategy

Sanofi’s ambitious DE&I strategy was launched in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can bring the best of their whole selves and engaging with the company’s diverse communities.

Read more information on Sanofi’s DE&I strategy .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Victor Rouault |  40 | 

Evan Berland | |

Timothy Gilbert |  9 |

Sally Bain |  6 | 

Investor Relations

Eva Schaefer-Jansen |  39 | 

Arnaud Delépine |  93 |

Corentine Driancourt |  21 |

Felix Lauscher | + 1 908 612 7239 |

Tarik Elgoutni| 7 |

Nathalie Pham |  17 |


* Specific criteria identifying the conditions and circumstances that are eligible for coverage under this program might be governed by the terms and conditions of country-specific policies or legal requirements.

1

2

3 Binder, V. Gany, F., (2020) Impact of Cancer on Employment. Journal of Clinical Oncology, 2020 Feb 1; 38(4): 302-309.

 



 

Attachment



EN
05/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Beyfortus study published in The Lancet Infectious Dise...

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rom...

 PRESS RELEASE

Communiqué de presse : L’étude sur Beyfortus publiée dans la revue The...

Communiqué de presse : L’étude sur Beyfortus publiée dans la revue The Lancet Infectious Diseases montre ses bénéfices chez les nourrissons au-delà de la première saison du VRS L’étude sur Beyfortus publiée dans la revue The Lancet Infectious Diseases montre ses bénéfices chez les nourrissons au-delà de la première saison du VRS La première étude montre que les nourrissons vaccinés contre le VRS pendant leur première saison avaient moins d’hospitalisations pour le VRS pendant leur deuxième saison L’étude a également montré une réduction de 85,9 % des hospitalisations pour infection des voi...

Research Department
  • Research Department

INFORME DIARIO 12 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...

COMPAÑÍAS QUE APARECEN EN EL INFORME: EUROPA: AB INBEV, AHOLD DELHAIZE, ASML, DEUTSCHE TELEKOM, ESSILORLUXOTTICA, MERCEDES BENZ GROUP, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El dato de empleo en EE.UU. agita los mercados Jornada de más a menos en las bolsas europeas, que ...

 PRESS RELEASE

Press Release: Belén Garijo to become Chief Executive Officer of Sanof...

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson’s last day as Chief Executive Officer will be on February 17, 2026 at the end of business. The Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years. Following the proposal of the Appointments Committee, the Board of Directors app...

 PRESS RELEASE

Communiqué de presse : Belén Garijo nommée Directrice générale de Sano...

Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul Hudson. Par conséquent, Paul Hudson quittera ses fonctions de Directeur général le 17 février 2026 au soir. Le Conseil le remercie pour sa contribution significative à la transformation et au développement du Groupe au cours des six dernières années. Sur proposition du Comité des nominations, le Conseil d’a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch